Thromboxane A2 receptor antagonism by flavonoids: Structure-activity relationships

Journal of Agricultural and Food Chemistry

Volumn 57, Issue 4, 2009, Pages 1589-1594

  Navarro Núñez, Leyre ^a   Castillo, Julian ^b   Lozano, María Luisa ^a   Martínez, Constantino ^a   Benavente García, Obdulio ^b   Vicente, Vicente ^a   Rivera, Jose ^a  

^a UNIVERSITY OF MURCIA   (Spain)

^b 80320 Alcantarilla   (Spain)

Author keywords

Antagonism; Flavonoids; Platelets; Sar; Txa2 receptor

Indexed keywords

7 [3 [(4 PHENYLSEMICARBAZIDO)METHYL] 7 OXABICYCLO[2.2.1]HEPT 2 YL] 5 HEPTENOIC ACID; FLAVONOID; HYDRAZINE DERIVATIVE; THROMBOXANE A2 RECEPTOR; TRITIUM;

ARTICLE; CHEMISTRY; DRUG ANTAGONISM; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; THROMBOCYTE;

BLOOD PLATELETS; FLAVONOIDS; HUMANS; HYDRAZINES; RECEPTORS, THROMBOXANE A2, PROSTAGLANDIN H2; STRUCTURE-ACTIVITY RELATIONSHIP; TRITIUM;

EID: 64549123135     PISSN: 00218561     EISSN: None     Source Type: Journal    
DOI: 10.1021/jf803041k     Document Type: Article

References (34)

1. Nakahata, N. Thromboxane A2: physiology/pathophysiology, cellular signal transduction and pharmacology. Pharmacol. Ther. 2008, 118, 18-35.
2. Huang, J. S.; Ramamurthy, S. K.; Lin, X.; Le Breton, G. C. Cell signalling through thromboxane A2 receptors. Cell. Signal. 2004, 16, 521-533.
3. Fitzgerald, G. A. Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am. J. Cardiol. 1991, 68, 11B-15B.
4. Brass, L. F.; Zhu, L.; Stalker, T. J. Minding the gaps to promote thrombus growth and stability. J. Clin. Invest. 2005, 115, 3385-3392.
5. Davi, G.; Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 2007, 357, 2482-2494.
6. Niccoli, G.; Giubilato, S.; Russo, E.; Spaziani, C.; Leo, A.; Porto, I.; Leone, A. M.; Burzotta, F.; Riondino, S.; Pulcinelli, F.; Biasucci, L. M.; Crea, F. Plasma levels of thromboxane A2 on admission are associated with no-reflow after primary percutaneous coronary intervention. Eur. Heart J. 2008, 29, 1843-1850.
7. Osende, J. I.; Shimbo, D.; Fuster, V.; Dubar, M.; Badimon, J. J. Antithrombotic effects of S 18886, a novel orally active thromboxane A2 receptor antagonist. J. Thromb. Haemost. 2004, 2, 492-498.
8. Hanson, J.; Dogne, J. M.; Ghiotto, J.; Moray, A. L.; Kinsella, B. T.; Pirotte, B. Design, synthesis, and SAR study of a series of N-alkyl- N'-[2-(aryloxy) -5-nitrobenzenesulfonyl]ureas and -cyan-oguanidine as selective antagonists of the TPα and TPβ; isoforms of the human thromboxane A2 receptor. J. Med. Chem. 2007, 50, 3928-3936.
9. Meadows, T. A.; Bhatt, D. L. Clinical aspects of platelet inhibitors and thrombus formation. Circ. Res. 2007, 100, 1261-1275.
10. Gasparyan, A. Y.; Watson, T.; Lip, G. Y. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J. Am. Coll. Cardiol. 2008, 51, 1829-1843.
11. Patrono, C.; Garcia Rodriguez, L. A.; Landolfi, R.; Baigent, C. Low-dose aspirin for the prevention of atherothrombosis. N. Engl. J. Med. 2005, 353, 2373-2383.
12. Awtry, E. H.; Loscalzo, J. Aspirin. Circulation 2000, 101, 1206-1218.
13. Khasawneh, F. T.; Huang, J. S.; Turek, J. W.; Breton, G. C. Differential mapping of the amino acids mediating agonist and antagonist coordination with the human thromboxane A2 receptor protein. J. Biol. Chem. 2006, 281, 26951-26965.
14. Ruan, K. H; Wu, J.; So, S. P.; Jenkins, L. A.; Ruan, C. H. NMR structure of the thromboxane A2 receptor ligand recognition pocket. Eur. J. Biochem. 2004, 271, 3006-3016.
15. Turek, J. W.; Halmos, T; Sullivan, N. L.; Antonakis, K.; Le Breton, G. C. Mapping of a ligand-binding site for the human thromboxane A2 receptor protein. J. Biol. Chem. 2002, 277, 16791-16797.
16. Scalbert, A.; Johnson, I. T.; Saltmarsh, M. Polyphenols: antioxi-dants and beyond. Am. J. Clin. Nutr. 2005, 81, 215S-2217.
17. Stevenson, D. E.; Hurst, R. D. Polyphenolic phytochemicals-just antioxidants or much more? Cell. Mol. Life Sci. 2007, 64, 2900-2916.
18. Guerrero, J. A.; Lozano, M. L.; Castillo, J.; Benavente-Garcia, O.; Vicente, V.; Rivera, J. Flavonoids inhibit platelet function through binding to the thromboxane A2 receptor. J. Thromb. Haemost. 2005, 3, 369-376.
19. Guerrero, J. A.; Navarro-Nuñez, L.; Lozano, M. L.; Martinez, C.; Vicente, V.; Gibbins, J. M.; Rivera, J. Flavonoids inhibit the platelet TxA (2) signalling pathway and antagonize TxA (2) receptors (TP) in platelets and smooth muscle cells. Br. J. Clin. Pharmacol. 2007, 64, 133-144.
20. Navarro-Nuñez, L.; Lozano, M. L.; Palomo, M.; Martinez, C.; Vicente, V.; Castillo, J.; Benavente-Garcia, O.; Diaz-Ricart, M.; Escolar, G; Rivera, J. Apigenin inhibits platelet adhesion and thrombus formation and synergizes with aspirin in the suppression of the arachidonic acid pathway. J. Agric. Food Chem. 2008, 56, 2970-2976.
21. Hodek, P.; Trefil, P.; Stiborova, M. Flavonoids-potent and versatile biologically active compounds interacting with cytochromes P450. Chem.-Biol. Interact. 2002, 139, 1-21.
22. Amic, D.; Davidovic-Amic, D.; Beslo, D.; Rastija, V.; Lucic, B.; Trinajstic, N. SAR and QSAR of the antioxidant activity of flavonoids. Curr. Med. Chem. 2007, 14, 827-845.
23. Boumendjel, A.; Boccard, J.; Carrupt, P. A.; Nicolle, E.; Blanc, M.; Geze, A.; Choisnard, L.; Wouessidjewe, D.; Matera, E. L.; Dumontet, C. Antimitotic and antiproliferative activities of chalcones: forward structure-activity relationship. J. Med. Chem. 2008, 51, 2307-2310.
24. Yañez, J.; Vicente, V.; Alcaraz, M.; Castillo, J.; Benavente-Garcia, O.; Canteras, M.; Teruel, J. A. Cytotoxicity and antiproliferative activities of several phenolic compounds against three melanocytes cell lines: relationship between structure and activity. Nutr. Cancer 2004, 49, 191-199.
25. Kato, A.; Nasu, N; Takebayashi, K.; Adachi, I.; Minami, Y.; Sanae, F.; Asano, N; Watson, A. A.; Nash, R. J. Structure-activity relationships of flavonoids as potential inhibitors of glycogen phosphorylase. J. Agric. Food Chem. 2008, 56, 4469-4473.
26. Benavente-Garcia, O.; Castillo, J.; Alcaraz, M.; Vicente, V.; Del Rio, J. A.; Ortuño, A. Beneficial action of citrus flavonoids on multiple cancer-related biological pathways. Curr. Cancer Drug Targets 2007, 7, 795-809.
27. Benavente-Garcia, O.; Castillo, J. Update on uses and properties of citrus flavonoids: new findings in anticancer, cardiovascular, and anti-inflammatory activity. J. Agric. Food Chem. 2008, 56, 6185-6205.
28. Pratico, D.; Cheng, Y.; Fitzgerald, G. A. TP or not TP: primary mediators in a close runoff. Arterioscler. Thromb. Vasc. Biol. 2000, 20, 1695-1698.
29. Hackam, D. G; Eikelboom, J. W. Antithrombotic treatment for peripheral arterial disease. Heart 2007, 93, 303-308.
30. Belhassen, L.; Pelle, G; Dubois-Rande, J. L.; Adnot, S. Improved endothelial function by the thromboxane A2 receptor antagonist S 18886 in patients with coronary artery disease treated with aspirin. J. Am. Coll. Cardiol. 2003, 41, 1198-1204.
31. O'Donnell, M. J.; Hankey, G. J.; Eikelboom, J. W. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. Stroke 2008, 39, 1638-1646.
32. Worth, N. F.; Berry, C. L.; Thomas, A. C.; Campbell, J. H. S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits. Atherosclerosis 2005, 183, 65-73.
33. Egan, K. M.; Wang, M.; Lucitt, M. B.; Zukas, A. M.; Pure, E.; Lawson, J. A.; FitzGerald, G. A. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005, 111, 334-342.
34. Jacobson, K. A.; Moro, S.; Manthey, J. A.; West, P. L.; Ji, X. D. Interactions of flavones and other phytochemicals with adenosine receptors. Adv. Exp. Med. Biol. 2002, 505, 163-171.